摘要
嵌合抗原受体T(CAR-T)细胞疗法已成为恶性血液病的重要治疗手段。然而,虚弱患者由于生理功能衰退、合并症多及免疫微环境的改变等,可能面临更高的治疗风险及更差的预后。本综述旨在探讨虚弱的评估工具,总结虚弱患者的临床疗效数据,分析虚弱对疗效的影响机制,并提出基于虚弱患者的管理策略,以期优化治疗结局。
Chimeric antigen receptor(CAR)-T cell therapy has become an important treatment for malignant haematological diseases.However,frail patients may face higher therapeutic risks and poorer prognosis due to physiological decline,multiple comorbidities and altered immune microenvironment.The aim of this review is to explore assessment tools for frailty,summarize clinical outcome data of frail patients,analyze the mechanisms by which frailty affects outcome,and propose frailty-based management strategies with a view to optimising treatment outcomes in frailty.
作者
杨慧
贺少龙
田卫伟
YANG Hui;HE Shao-long;TIAN Wei-wei(Department of Hematology,The Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Shanxi Taiyuan 030032,China)
出处
《内科急危重症杂志》
2025年第2期165-170,192,共7页
Journal of Critical Care In Internal Medicine
基金
山西省自然科学基金面上项目(202303021211224,202403021211164)。
关键词
虚弱
恶性血液病
嵌合抗原受体T细胞治疗
Frailty
Malignant hematological diseases
Chimeric antigen receptor-T cell therapy
